• The results revealed that central systolic blood pressure (cSBP) and central pulse pressure (cPP) showed higher hazard ratios for cardiovascular events compared to their peripheral pressure counterparts at age of 60 and older.• The investigators concluded that central blood pressure monitoring improved prediction of cardiovascular events compared to standard peripheral pressure measurements.• This provides further evidence that cardiovascular risk is better characterized by central blood pressure than traditional brachial pressure, which facilitates better individualization of care for these patients.• Central blood pressure waveform analysis with SphygmoCor facilitates improved patient management by facilitating management of central pressures while also treating patients to their goal outcomes based on current blood pressure guidelines.• AtCor Medical’s SphygmoCor technology is approved by the CFDA and commercially available to hospitals and healthcare facilities across China.
- Forums
- ASX - By Stock
- CDX
- Can CardieX match Omron?
Can CardieX match Omron?, page-4
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CDX (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.5¢ |
Change
-0.015(10.0%) |
Mkt cap ! $17.65M |
Open | High | Low | Value | Volume |
15.5¢ | 17.5¢ | 13.5¢ | $209.1K | 1.362M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 23000 | 13.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
14.5¢ | 30600 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 425123 | 0.038 |
3 | 346111 | 0.037 |
4 | 480000 | 0.036 |
8 | 1270000 | 0.035 |
1 | 100000 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 250000 | 1 |
0.040 | 328240 | 6 |
0.041 | 500000 | 1 |
0.042 | 182564 | 2 |
0.043 | 762158 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
CDX (ASX) Chart |